AURANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Aura Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$6.29+0.19 (+3.11%)
Close on Oct 19, 2026
- Market cap
- $596.69M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.62 (+10.93%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $596.69M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.89
- Dividend yield
- –
- Free cash flow yield
- -17.32%
Fundamentals
- Net income
- -$131.01M
- EPS, diluted
- -$1.76
- Free cash flow
- -$103.35M
- Book value per share
- $3.32
- Diluted shares
- 95M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$138.08M
Net income
-$131.01M
EPS, diluted
-$1.76
Free cash flow
-$103.35M
Reported periodTrailing twelve months